Immunonutrition in intensive care has not yet demonstrated a beneficial effect on organ failure, the acquisition of nosocomial infections, or mortality. It did not correct for acquired immunosuppression in intensive care patients. Despite numerous methodological problems (use of several pharmaconutrients, very heterogeneous set of patients) and the absence of clinical data, deleterious effects have been attributed to immunonutrition in intensive care, in particular in septic patients and patients in intensive care . Arginine (ARG) is a semi-essential amino acid involved in many immunological mechanisms. It is synthesized in sufficient quantity under normal conditions but quickly becomes insufficient under catabolic conditions such as in severe sepsis. Arginine is not only the precursor of nitrogen monoxide (NO) but also an essential substrate for numerous enzymatic reactions which participate in the maintenance of immune homeostasis, in particular T lymphocyte function. Depletion of the cellular medium in arginine will induce an abnormality in the metabolism of immune cells responsible for a dysfunction of these cells (lymphopenia linked to early apoptosis) and thus expose patients to organ failure and nosocomial infections. It has been found that hypoargininemia in intensive care patients is associated with the persistence of organ dysfunction (SOFA score), the occurrence of nosocomial infections and mortality. Also, it has been demonstrated that in these patients, enteral administration of ARG was not deleterious and increased ornithine synthesis, suggesting a preferential use of ARG via the arginases route, without significant increase in argininaemia or effect on immune functions. L-citrulline (CIT), an endogenous precursor of ARG, constitutes an interesting alternative for increasing the availability of ARG. Sponsor recent data demonstrate that the administration of CIT in intensive care is not deleterious and that it very significantly reduces mortality in an animal model of sepsis, corrects hypoargininemia, with convincing data on immunological parameters such as lymphopenia, which is associated with mortality, organ dysfunction and the occurrence of nosocomial infections. The availability of ARG directly impacts the mitochondrial metabolism of T lymphocytes and their function. Our hypothesis is therefore that CIT supplementation is more effective than administration of ARG in correcting hypoargininemia, reducing lymphocyte dysfunction, correcting immunosuppression and organ dysfunction in septic patients admitted to intensive care.
Strategy : Enteral administration of citrulline for 5 days versus iso-nitrogenous placebo. Amino acid assay and immunological parameters (monocytic expression of HLA-DR, MDSCs, cytokines / chemokines, lymphocyte number and phenotype, apoptosis and lymphocyte proliferation and mitochondrial function and T lymphocyte repertoire) will only be carried out on patients included in Rennes (60 patients).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
130
Enteral administration of citrulline for 5 days.
Enteral administration of iso-nitrogenous placebo for 5 days.
Rennes University Hospital - Medical ICU
Rennes, Brittany Region, France
RECRUITINGRennes University Hospital - Surgical ICU
Rennes, Brittany Region, France
TERMINATEDBesançon University Hospital
Besançon, France
RECRUITINGLe Mans Hospital
Le Mans, France
RECRUITINGTours University Hospital
Tours, France
RECRUITINGSOFA score
SOFA score for organ failure (5 parameters ranged from 0 to 4 each)
Time frame: Baseline and day 7 or last known SOFA score if the patient died or left intensive care before day 7.
Nosocomial infections
Incidence of nosocomial infections during the stay in intensive care (maximum Day 28). The diagnosis of nosocomial infections will be made by following the definitions of nosocomial infections of the CDC (Centers for Disease Control). An independent committee of experts will validate or not the infections.
Time frame: From Inclusion up to Day 28 maximum
Exposure to each antibiotic
Number of days of exposure to each antibiotic per 1000 days of hospitalization (maximum Day 28)
Time frame: Up to Day 28 maximum
Mortality in intensive care
Mortality in intensive care
Time frame: Up to Day 28 maximum
Hospital mortality
Hospital mortality
Time frame: Up to Day 28 maximum
Number and phenotypes of lymphocytes
Number and phenotypes of lymphocytes on Day 1, Day 3 and Day 7
Time frame: Day 1, 3 and 7
HLA-DR monocytic expression
HLA-DR monocytic expression (flow cytometry) on Day 1, Day 3 and Day 7
Time frame: Day 1, 3 and 7
Number of Myeloid-derived suppressor cells
Number of Myeloid-derived suppressor cells (flow cytometry) at on Day 1, Day 3 and Day 7
Time frame: Day 1, 3 and 7
Plasma cytokines / chemokines
Plasma cytokines / chemokines (IL-6, IL-8, IL-10, IL-7, CXCL10, G-CSF, TNF-alpha, IFN-β) on on Day 1, Day 3 and Day 7
Time frame: Day 1, 3 and 7
T repertoire
Diversity of the T repertoire at Day 1, Day 3 and Day 7
Time frame: Day 1, 3 and 7
T lymphocyte exhaustion
T lymphocyte exhaustion: measurement of lymphocytic apoptosis and lymphocyte proliferation on Day 1, Day 3 and Day 7
Time frame: Day 1, 3 and 7
Mitochondrial activity
Measurement of mitochondrial activity (measurement of the number of mitochondria and their membrane potential, measurement of Beclin1 expression) on Day 1, Day 3 and Day 7
Time frame: Day 1, 3 and 7
Plasma amino acids
Plasma amino acids (arginine and its metabolites (ornithine, glutamate, glutamine, citrulline, proline) and tryptophan / kynurenine) on Day 1, Day 3 and Day 7
Time frame: Day 1, 3 and 7
SOFA score
SOFA score for organ failures on Day 3 and Day 5 (5 parameters ranged from 0 to 4 each)
Time frame: Day 3 and Day 5
Duration of hospitalization in intensive care
Duration of hospitalization in intensive care (days), up to Day 28 maximum
Time frame: Up to Day 28 maximum
Duration of hospitalization at the hospital
Hospital stay at the hospital (days), up to Day 28 maximum
Time frame: Up to Day 28 maximum
Duration of mechanical ventilation
Duration of mechanical ventilation (days), up to Day 28 maximum.
Time frame: Up to Day 28 maximum
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.